← Leaderboards
Stephen H Tsang
University Of California Los Angeles
$18,411,197
Attributed
$36,562,150
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,562,150 · 10
By mechanism
R24$19,489,794 · 2
R01$14,115,582 · 4
U01$2,035,973 · 2
K08$489,851 · 1
R21$430,950 · 1
Top collaborators
- Alexander G Bassuk11 shared
- Vinit B Mahajan11 shared
- Janet R. Sparrow7 shared
- William W Hauswirth6 shared
- Stylianos Michalakis6 shared
- Simon Petersen-Jones6 shared
- Isabelle Audo5 shared
- James Bryant Hurley4 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Sue S. Yom$1,250,560
- Lutz Birnbaumer$1,910,878
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesMutationAffectRetinaRetinitis PigmentosaGene TherapyMediatingAllelesInheritedPhotoreceptorsMouse ModelRetinal DiseasesRetinal DegenerationVisionRetinal ConePhotoreceptor DegenerationCellsElectroretinographyRepairedClustered Regularly Interspaced Short Palindromic RepeatsClinical TrialsVectorAmericanCessation Of Life
Grant awards (61)
Enhancing cone survival in retinitis pigmentosa through cell-specific therapeutic CRISPR editing of a roxadustat target$450,345
R01 · FY2025 · EY · contact PI
Gene Editing and Silencing in Phototransduction$405,751
R01 · FY2025 · EY · contact PI
Defining Barriers to Gene Therapy$405,751
R01 · FY2025 · EY · contact PI
Therapeutic gene editing and multimodal imaging in juvenile macular degenerationÂ$2,153,230
R24 · FY2024 · EY · contact PI
Enhancing cone survival in retinitis pigmentosa through cell-specific therapeutic CRISPR editing of a roxadustat target$529,818
R01 · FY2024 · EY · contact PI
Identification of the specific risk allele responsible for oxidative stress in ARMS2/HTRA1-related AMD$408,580
U01 · FY2024 · EY · contact PI
Gene Editing and Silencing in Phototransduction$405,911
R01 · FY2024 · EY · contact PI
Defining Barriers to Gene Therapy$405,911
R01 · FY2024 · EY · contact PI
Defining Barriers to Gene Therapy$95,661
R01 · FY2024 · EY · contact PI
Therapeutic gene editing and multimodal imaging in juvenile macular degenerationÂ$2,178,277
R24 · FY2023 · EY · contact PI
Enhancing cone survival in retinitis pigmentosa through cell-specific therapeutic CRISPR editing of a roxadustat target$529,817
R01 · FY2023 · EY · contact PI
Identification of the specific risk allele responsible for oxidative stress in ARMS2/HTRA1-related AMD$408,659
U01 · FY2023 · EY · contact PI
Gene Editing and Silencing in Phototransduction$406,067
R01 · FY2023 · EY · contact PI
Defining Barriers to Gene Therapy$332,130
R01 · FY2023 · EY · contact PI
Therapeutic gene editing and multimodal imaging in juvenile macular degenerationÂ$2,189,617
R24 · FY2022 · EY · contact PI
Translational Gene Therapy for CNGB1 Retinitis Pigmentosa$1,517,749
R24 · FY2022 · EY
Enhancing cone survival in retinitis pigmentosa through cell-specific therapeutic CRISPR editing of a roxadustat target$545,461
R01 · FY2022 · EY · contact PI
Identification of the specific risk allele responsible for oxidative stress in ARMS2/HTRA1-related AMD$408,734
U01 · FY2022 · EY · contact PI
Gene Silencing and Gene Editing in Phototransduction$390,438
R01 · FY2022 · EY · contact PI
Defining Barriers to Gene Therapy$346,866
R01 · FY2022 · EY · contact PI
Therapeutic gene editing and multimodal imaging in juvenile macular degenerationÂ$2,189,617
R24 · FY2021 · EY · contact PI
Translational Gene Therapy for CNGB1 Retinitis Pigmentosa$1,828,029
R24 · FY2021 · EY
Gene Silencing and Gene Editing in Phototransduction$390,438
R01 · FY2021 · EY · contact PI
Translational Gene Therapy for CNGB1 Retinitis Pigmentosa$363,550
R24 · FY2021 · EY
Defining Barriers to Gene Therapy$346,866
R01 · FY2021 · EY · contact PI
Therapeutic gene editing and multimodal imaging in juvenile macular degenerationÂ$2,200,637
R24 · FY2020 · EY · contact PI
Translational Gene Therapy for CNGB1 Retinitis Pigmentosa$1,832,126
R24 · FY2020 · EY
Precision genome surgery in autologous stem cell transplant$405,000
U01 · FY2020 · EY · contact PI
Gene Silencing and Gene Editing in Phototransduction$360,990
R01 · FY2020 · EY · contact PI
Defining Barriers to Gene Therapy$357,594
R01 · FY2020 · EY · contact PI
Translational Gene Therapy for CNGB1 Retinitis Pigmentosa$1,783,428
R24 · FY2019 · EY
Precision genome surgery in autologous stem cell transplant$405,000
U01 · FY2019 · EY · contact PI
Mechanistic Studies on Regenerative Medicine Approaches to Childhood Blindness$389,825
R01 · FY2019 · EY
Defining Barriers to Gene Therapy$356,603
R01 · FY2019 · EY · contact PI
Gene Silencing and Gene Editing in Phototransduction$336,225
R01 · FY2019 · EY · contact PI
Translational Gene Therapy for CNGB1 Retinitis Pigmentosa$1,253,534
R24 · FY2018 · EY
Gene Silencing and Gene Editing in Phototransduction$394,762
R01 · FY2018 · EY · contact PI
Mechanistic Studies on Regenerative Medicine Approaches to Childhood Blindness$389,825
R01 · FY2018 · EY
Defining Barriers to Gene Therapy$381,663
R01 · FY2018 · EY · contact PI
Defining Barriers to Gene Therapy$400,000
R01 · FY2017 · EY · contact PI
Gene Silencing and Gene Editing in Phototransduction$394,762
R01 · FY2017 · EY · contact PI
Mechanistic Studies on Regenerative Medicine Approaches to Childhood Blindness$389,825
R01 · FY2017 · EY
Mechanistic Studies on Regenerative Medicine Approaches to Childhood Blindness$402,348
R01 · FY2016 · EY
Defining Barriers to Gene Therapy$400,000
R01 · FY2016 · EY · contact PI
Gene Silencing and Gene Editing in Phototransduction$394,762
R01 · FY2016 · EY · contact PI
Evaluating GWAS AMD Candidate Loci by Gene Editing in Human iPS Cells$145,591
R21 · FY2016 · AG
Evaluating GWAS AMD Candidate Loci by Gene Editing in Human iPS Cells$51,236
R21 · FY2016 · AG
Gene Silencing and Gene Editing in Phototransduction$408,714
R01 · FY2015 · EY · contact PI
Defining Barriers to Gene Therapy$392,000
R01 · FY2015 · EY · contact PI
Evaluating GWAS AMD Candidate Loci by Gene Editing in Human iPS Cells$234,123
R21 · FY2015 · AG
Defining Barriers to Gene Therapy$400,000
R01 · FY2014 · EY · contact PI
Toward mechanism- and gene-based therapies for retinal degeneration$309,120
R01 · FY2012 · EY · contact PI
Toward mechanism- and gene-based therapies for retinal degeneration$309,120
R01 · FY2011 · EY · contact PI
Toward mechanism- and gene-based therapies for retinal degeneration$318,780
R01 · FY2010 · EY · contact PI
Toward mechanism- and gene-based therapies for retinal degeneration$320,833
R01 · FY2009 · EY · contact PI
Toward mechanism- and gene-based therapies for retinal degeneration$320,600
R01 · FY2008 · EY · contact PI
TAMOXIFEN-INDUCED KNOCK-OUT OF A RETINAL GENE$114,943
K08 · FY2005 · EY
TAMOXIFEN-INDUCED KNOCK-OUT OF A RETINAL GENE$111,561
K08 · FY2003 · EY
TAMOXIFEN-INDUCED KNOCK-OUT OF A RETINAL GENE$108,309
K08 · FY2002 · EY
TAMOXIFEN-INDUCED KNOCK-OUT OF A RETINAL GENE$79,500
K08 · FY2001 · EY
TAMOXIFEN-INDUCED KNOCK-OUT OF A RETINAL GENE$75,538
K08 · FY2000 · EY